The presentation will be accessible via a Webcast through a link posted on the Investors, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay for 14 days following the date of the presentation.
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco,
Jennifer Ruddock of Nektar Therapeutics
Jodi Sievers of Nektar Therapeutics
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-to-webcast-presentation-at-ubs-global-healthcare-conference-2017-in-new-york-300457593.html
News Provided by Acquire Media